UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

\mathbf{c}			\T	T T	40	O / A
	(· H		11		14	G/A
J		الناا	JU	نايا	LU	$\mathbf{U}/\mathbf{\Lambda}$

Under the Securities Exchange Act of 1934 (Amendment No. 3)*

RAPT Therapeutics, Inc.

(Name of Issuer)

Common Stock, \$0.0001 par value per share (Title of Class of Securities)

75382E 109 (CUSIP Number)

December 31, 2022 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
⊠ Rule 13d-1(c)

☐ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 75382E 109

1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)				
	Perceptive A	dvis	ors LLC		
2					
3	3 SEC USE ONLY				
4	4 CITIZENSHIP OR PLACE OF ORGANIZATION				
	Delaware				
		5	SOLE VOTING POWER		
N	UMBER OF		0		
	SHARES	6	SHARED VOTING POWER		
	NEFICIALLY WNED BY		1,798,955		
_	EACH	7	SOLE DISPOSITIVE POWER		
	EPORTING PERSON		0		
	WITH:	8	SHARED DISPOSITIVE POWER		
			1,798,955		
9	AGGREGAT	ΓΕ Α	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	1,798,955				
10					
11					
	5.3%				
12					
	T.A.				
	IA				

CUSIP No. 75382E 109

1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)				
	Joseph Edelr	nan			
2					
3	3 SEC USE ONLY				
4	CITIZENSHIP OR PLACE OF ORGANIZATION				
	United States of America				
		5	SOLE VOTING POWER		
N	UMBER OF		0		
	SHARES	6	SHARED VOTING POWER		
	NEFICIALLY WNED BY		1,798,955		
١	EACH	7	SOLE DISPOSITIVE POWER		
R	EPORTING	/	SOLE DISFOSITIVE FOWER		
	PERSON		0		
	WITH:	8	SHARED DISPOSITIVE POWER		
			1,798,955		
9	AGGREGAT	ГΕΑ	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	1,798,955				
10		X IF	THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		
11					
	5.3%				
12	= 12.1				
	1112 01 10				
	IN				

CUSIP No. 75382E 109

1	1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)				
	Perceptive L	ife Sciences Master Fund, Ltd.			
2		E APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) b) \square			
3	3 SEC USE ONLY				
4	4 CITIZENSHIP OR PLACE OF ORGANIZATION				
	Cayman Islands				
		5 SOLE VOTING POWER			
N	UMBER OF	0			
	SHARES	6 SHARED VOTING POWER			
	NEFICIALLY WNED BY	1,798,955			
	EACH EPORTING	7 SOLE DISPOSITIVE POWER			
K	PERSON	0			
WITH: 8 SHARED DISPOSITIVE POWER		8 SHARED DISPOSITIVE POWER			
		1,798,955			
9	AGGREGAT	TE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	1,798,955				
10	CHECK BO	X IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)			
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9				
	5.3%				
12					
	CO				

Item 1(a). Name of Issuer:

RAPT Therapeutics, Inc. (the "Issuer")

Item 1(b). Address of Issuer's Principal Executive Offices:

561 Eccles Avenue, South San Francisco, CA 94080

Item 2(a). Names of Persons Filing:

The names of the persons filing this report (collectively, the "Reporting Persons") are:

Perceptive Advisors LLC ("Perceptive Advisors")

Joseph Edelman ("Mr. Edelman")

Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")

Item 2(b). Address of Principal Business Office or, if None, Residence:

The address of the principal business office of each of the Reporting Persons is:

51 Astor Place, 10th Floor New York, NY 10003

Item 2(c). <u>Citizenship</u>:

Perceptive Advisors is a Delaware limited liability company

Mr. Edelman is a United States citizen

The Master Fund is a Cayman Islands corporation

Item 2(d). <u>Title of Class of Securities</u>:

Common Stock, \$0.0001 par value per share ("Common Stock")

Item 2(e). <u>CUSIP Number</u>:

75382E 109

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4. Ownership.

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 33,940,217 shares of Common Stock outstanding as reported in the Issuer's prospectus supplement filed on November 18, 2022.

The Master Fund directly holds 1,798,955 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own such shares. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own such shares.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following \Box .

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8. <u>Identification and Classification of Members of the Group.</u>

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. <u>Certification</u>.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: February 14, 2023

PERCEPTIVE ADVISORS LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member

/s/ Joseph Edelman

JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC

By: <u>/s/ Joseph</u> Edelman

Name: Joseph Edelman Title: Managing Member

AGREEMENT

The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934.

Date: February 14, 2023

PERCEPTIVE ADVISORS LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member

/s/ Joseph Edelman

JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member